Teriparatide transdermal - TransPharma

Alternative Names: hPTH (1-34); ViaDerm-hPTH (1-34); ViaDor-hPTH (1-34)

Latest Information Update: 02 Oct 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator TransPharma Medical
Developer Eli Lilly and Company; TransPharma Medical
Class Diagnostic agents; Osteoporosis therapies; Peptide hormones; Skin disorder therapies
Mechanism of Action Osteogenesis stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

30 Sep 2011 Eli Lilly completes a phase II trial in Osteoporosis in Argentina, Estonia, Hungary, Mexico and Romania (NCT01011556)
11 May 2011 Eli Lilly completes a Phase-I clinical trial in Osteoporosis in USA, Germany and the United Kingdom (NCT01250145)
30 Nov 2010 Phase-I clinical trials in Osteoporosis in USA (Transdermal)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com